Table 6.
Recurrence rates of chemotherapy versus surveillance in studies with non-seminomatous GCT patients in cSI [22-24, 32, 33]
![Recurrence rates of chemotherapy versus surveillance in studies with non-seminomatous GCT patients in cSI [22-24, 32, 33]](https://karger.silverchair-cdn.com/karger/content_public/journal/uin/105/3-4/10.1159_000510407/2/000510407_t06.png?Expires=1757228399&Signature=V3XgZEVMA8gSQCbZwVH-gNVzXvp7onKGsOwrKu0WyLiZAVdDbaCC2nvQ9OuK~qjHb7S7JlruVm3VzBfWBrn-0TmUtoA1TOy1QgMqRjRk4T3Z0rPzpQpvo2vKeRFKjC7djkN9Q4XBrVgMrdjQGqtZpvONrMbk6Od2CX6B6IeWa6KXTIzZI8E9aC~Q34AFJ3QFolz1XbynVeNPirYyDsSNHIu9KWIxBdyKndKI7hfNYZPNPVKQchdtj6Sv2DzdC7vdM4srHAHbKCG8nPTYDUvWZKHtiVz1L5SyW97SBc1m9vL-JLMisUXlCnfVmIh9pDsdVAknUwg0q8YrlUy~2T-Ylw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Recurrence rates of chemotherapy versus surveillance in studies with non-seminomatous GCT patients in cSI [22-24, 32, 33]
